Stock Report

Download full stock data and analysis for free Last Updated: 31-Aug-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Clear All

Nectar Lifescience Peer Comparison

Stock Card factsheet watchlist-stock-modal share-fund-plan-icon

NSE: NECLIFE | BSE: 532649

₹12.60

up-down-arrow ₹0.13 (1.04%)

As on 31-Aug-2026 10:54IST

Market cap

info icon

₹242 Cr

Revenue (TTM)

info icon

₹7 Cr

P/E Ratio

info icon

--

P/B Ratio

info icon

0.4

Div. Yield

info icon

0 %

Edit peer-selector-edit
Nectar Lifescience Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Market cap (₹ Cr)
 242 35,497 29,798 16,589 15,507
Revenue (₹ Cr)
 7 9,683 2,372 2,590 1,108
Net Profit (₹ Cr)
 -245.06 1,018.97 497.77 603.02 270.18
Net Margin (%)
 82.84 10.47 20.72 22.63 23.29
RoE (%)
 -1.21 21.30 28.49 19.61 14.45
Price to Earnings
 -- 35.10 59.86 27.51 56.31
Price-To-Book
 0.43 6.79 14.74 4.76 7.48

Income Statement (₹ Cr)

Nectar Lifescience Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Operating Revenue arrow
7.44 9,683.45 2,371.81 2,590.40 1,108.39
Total Income arrow
17.34 9,730.84 2,402.61 2,664.23 1,159.90
Total Expenditure arrow
94.20 7,739.53 1,608.91 1,753.71 720.01
EBITDA arrow
-86.76 1,943.92 762.90 836.69 388.38
Depreciation arrow
0.46 425.10 98.11 78.88 74.78
EBIT arrow
-87.22 1,518.82 664.79 757.81 313.60
Interest arrow
36.28 148.45 26.33 5.43 0.26
Other Income arrow
9.90 47.39 30.80 73.83 51.50
Exceptional Items arrow
88.15 -27.85 0.00 -25.66 -3.28
Profit before Tax arrow
-25.46 1,389.91 669.26 800.55 361.56
Provision for Tax arrow
-39.82 370.94 171.48 197.53 91.39
Profit after Tax arrow
14.36 1,018.97 497.77 603.02 270.18

Liabilities (₹ Cr)

Nectar Lifescience Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Shareholder's Funds arrow
582.30 4,950.03 1,874.47 3,332.13 2,017.06
Minority Interest arrow
0.00 -7.58 0.00 0.00 2.51
Non-Current Liabilities arrow
13.26 723.57 345.47 142.73 50.51
Current Liabilities arrow
26.05 3,912.24 710.20 508.04 169.08
Total Liabilities arrow
621.61 9,514.48 2,930.14 4,157.10 2,231.79

Assets (₹ Cr)

Nectar Lifescience Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Non-Current Assets arrow
329.30 3,392.16 1,290.62 1,321.38 957.22
Current Assets arrow
252.97 5,612.10 1,483.13 2,649.36 1,250.11
Total Assets arrow
621.61 9,514.48 2,930.14 4,157.10 2,231.79
Total Debt* arrow
0.00 1,204.08 196.61 0.00 0.00
Net Current Assets arrow
226.92 1,699.86 772.93 2,141.33 1,081.04
Contingent Liabilities arrow
229.52 258.92 13.18 4.82 3.76

Cashflow (₹ Cr)

Nectar Lifescience Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Cash From Operating Activities arrow
-348.72 943.55 346.68 565.41 266.88
Cash Flow from Investing Activities arrow
1,208.15 -1,193.06 -423.73 -570.15 -142.72
Cash from Financing Activities arrow
-766.51 343.43 20.98 -64.34 -112.88
Net Cash Inflow / Outflow arrow
92.91 93.92 -56.08 -69.08 11.28

Ratios

Profitability Ratios

 Nectar Lifescience Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
ROCE (%) arrow
-4.75 25.25 27.50 24.61 18.04
ROE (%) arrow
-1.21 21.30 28.49 19.61 14.45
ROA (%) arrow
1.08 11.42 19.48 16.31 12.66
EBIT Margin (%) arrow
-1,171.85 15.68 28.03 29.25 28.29
Net Margin (%) arrow
82.84 10.47 20.72 22.63 23.29
Cash Profit Margin (%) arrow
0.00 0.00 0.00 0.00 0.00

Growth Ratios

 Nectar Lifescience Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Revenue Growth (%) arrow
29.44 18.36 78.33 7.93 -6.72
EBIT Growth (%) arrow
-5,157.44 30.43 303.07 19.88 -26.64
Net Profit Growth (%) arrow
84,594.12 32.39 182.61 21.66 -24.38
EPS Growth (%) arrow
-94,104.87 36.68 277.72 25.42 -21.99
Book Value Growth (%) arrow
-39.10 11.36 22.95 18.43 11.27

Valuation Ratios

 Nectar Lifescience Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Price / Earnings arrow
-17.44 34.38 59.86 26.64 55.82
Price / Book Value arrow
0.43 6.79 14.74 4.76 7.48
Dividend Yield (%) arrow
0.00 0.19 0.15 0.37 0.51
EV/EBITDA arrow
-1.35 18.80 38.85 18.89 38.86
Market Cap (₹ Cr) arrow
-- 30,257.56 15,412.11 11,956.86 10,627.92

Solvency Ratios

 Nectar Lifescience Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Debt to Equity arrow
0.00 0.05 0.09 0.00 0.00
Short term debt to equity ratio arrow
-- 0.16 -- -- --
Current Ratio arrow
9.71 1.43 2.09 5.21 7.39
Quick Ratio arrow
9.70 0.82 1.37 3.85 5.46
Interest Coverage arrow
0.30 10.36 26.41 148.49 1,386.30

Operating Efficiency Ratios

 Nectar Lifescience Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Debtors to sales (%) arrow
0.00 26.46 22.82 41.42 41.52
Asset Turnover arrow
0.01 1.09 0.93 0.70 0.52
Receivable days arrow
-- 88.68 77.32 144.58 169.86
Inventory Days arrow
-- 84.11 80.83 96.67 97.92
Payable days arrow
-- 176.65 125.94 135.45 159.68
Cash Conversion Cycle arrow
-- -3.86 32.22 105.80 108.11
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
loading...